• Company
• Xospata passed the first hurdle to increasing benefits
• by Eo, Yun-Ho May 8, 2023 05:41am

• Policy
• First reimbursement of Yuhan Pregabalin 75mg CR
• by Lee, Tak-Sun May 8, 2023 05:41am

• Opinion
• [Reporter's View] Suspension of drug price cut
• by Kim, Jin-Gu May 8, 2023 05:41am

• Company
• New polycythemia vera drug Besremi may be prescribed
• by Eo, Yun-Ho May 8, 2023 05:40am

• Company
• Merck establishes a bio-production facility in Daejeon
• by Jung, Sae-Im May 8, 2023 05:40am

• Company
• AbbVie Korea merges with Allergan Korea
• by Jung, Sae-Im May 7, 2023 08:37pm

• Company
• BeigeneKR's hematologic cancer drug Brukinsa, covered from M
• by Jung, Sae-Im May 4, 2023 05:50am

• Company
• Erleada can be prescribed at general hospitals in Korea
• by Eo, Yun-Ho May 4, 2023 05:50am

• Company
• Daewoong is accelerating its global expansion
• by Kim, Jin-Gu May 4, 2023 05:50am

• Company
• Rare diseases still left neglected in Korea’s healthcare
• by Eo, Yun-Ho May 4, 2023 05:49am